Progesterone after mifepristone – pilot for efficacy and reproducibility (PAMper Trial): a prospective single-arm clinical trial of progesterone after mifepristone for women whose decision has changed regarding medical termination of their pregnancy.

niversity of New England0 个研究点目标入组 52 人开始时间: 2020年5月22日最近更新: 2021年6月7日

适应症

试验速览

暂无简介。

•- have ingested mifepristone within the last 72 hours to initiate MTOP
•- have not taken any misoprostol;
•- have no contraindications for use of progesterone, including known allergy or hypersensitivity to progesterone or to any of the excipients, severe hepatic dysfunction, undiagnosed vaginal bleeding, known missed miscarriage or ectopic pregnancy, mammary or genital tract carcinoma, thromboembolic disorders, thrombophlebitis, cerebral haemorrhage, or porphyria.
•- live in Australia;
•- provide the name of their usual or nominated medical practitioner; and
•- understand English, or utilise the assistance of an accredited interpreter if appropriate.

•- are unable to take their first dose of progesterone within 72 hours of taking mifepristone;
•- are not living in Australia;
•- wish to continue with MTOP and take misoprostol; or
•- declined permission for communication between the trial coordinator and their usual or nominated medical practitioner regarding trial participation.

发起方

niversity of New England